|1.||Crandall, David L: 6 articles (07/2009 - 07/2004)|
|2.||Elokdah, Hassan: 5 articles (04/2008 - 07/2004)|
|3.||Vaughan, Douglas E: 3 articles (06/2012 - 02/2005)|
|4.||Eren, Mesut: 2 articles (06/2012 - 01/2006)|
|5.||Crandall, D L: 2 articles (09/2008 - 12/2006)|
|6.||Alessi, Marie-Christine: 2 articles (12/2006 - 10/2006)|
|7.||Hennan, James K: 2 articles (08/2005 - 07/2004)|
|8.||Coll, Julio: 1 article (11/2015)|
|9.||Estepa, Amparo: 1 article (11/2015)|
|10.||Raleigh, Matthew J: 1 article (07/2015)|
09/01/2008 - "In the vena cava protocol, PAI-039 pretreatment significantly reduced thrombus weight at PAI-039 doses of 3, 10 and 30 mg kg(-1). "
09/01/2008 - "Time to occlusive thrombosis was increased from 18.2 +/- 4.6 min in controls to 32.5 +/- 8.7 (P = ns), 46.1 +/- 7.0 (P < 0.05), and 41.6 +/- 11.3 min (P < 0.05) in the respective PAI-039 treatment groups. "
09/01/2008 - "To assess efficacy in a thrombosis prevention paradigm, PAI-039 was administered orally 90 min before injury (1-30 mg kg(-1)). "
04/01/2008 - "PAI-039 treatment was also associated with significantly increased return of inferior vena cava blood flow four days post-thrombosis versus controls (p < 0.05). "
08/01/2005 - "Although occlusive thrombosis was observed across all groups based upon the absence of measurable blood flow, a high incidence (>60%) of spontaneous reperfusion occurred only in those groups receiving PAI-039. "
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/2008 - "When PAI-039 was dosed in a treatment paradigm 4 h after stable arterial and venous thrombosis, a significant reduction in thrombus weight was observed 24 h later at PAI-039 doses of 3, 10 and 30 mg kg(-1). "
04/01/2008 - "This is the first study to demonstrate dose related effects of PAI-039 on increasing thrombus resolution and inferior vena cava blood flow without adverse effects on anti-coagulation in a rat stenosis model of venous thrombosis."
04/01/2008 - "Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis."
01/01/2015 - "Pharmacological inhibition of PAI-1 with PAI-039 blocked bevacizumab-induced venous thrombosis. "
04/01/2008 - "This study aimed to evaluate a small-molecule PAI-1 inhibitor (PAI-039; tiplaxtinin) in a rodent stenosis model of venous thrombosis in a two-phase experiment. "
12/01/2013 - "Treatment of T24 xenografts with tiplaxtinin resulted in inhibition of angiogenesis and induction of apoptosis, leading to a significant reduction in tumor growth. "
12/01/2006 - "An in vivo tumor angiogenesis model was used to assess the effect of PAI-039 administration on neovascularization in a Matrigel implant. "
12/01/2006 - "In a tumor angiogenesis model, PAI-039 treatment of wild-type mice dose-dependently decreased hemoglobin concentration and endothelial cell staining within the Matrigel implant, indicating reduced angiogenesis, but exhibited no in vivo efficacy in PAI-1 null mice. "
|4.||Wounds and Injuries (Trauma)
07/01/2015 - "Importantly, PAI-039 treatment significantly improved epidermal cellular migration and wound re-epithelialization compared with vehicle-treated STZ-diabetic mice. "
07/01/2015 - "These findings support the use of PAI-039 as a novel therapeutic agent to improve diabetic wound closure and demonstrate the primary mechanism of its action to be related to epidermal closure. "
07/01/2015 - "PAI-039 treatment failed to improve angiogenesis in the wounds of STZ-diabetic mice and blunted angiogenesis in the wounds of nondiabetic mice. "
07/01/2015 - "Inhibition of PAI-1 Via PAI-039 Improves Dermal Wound Closure in Diabetes."
|5.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/01/2015 - "It has been demonstrated that PAI-1-deficient mice exhibit improved cutaneous wound healing, and that PAI-1 inhibition improves skeletal muscle repair in mice with type 1 diabetes mellitus, leading us to hypothesize that pharmacologically mediated reductions in PAI-1 using PAI-039 would normalize cutaneous wound healing in streptozotocin (STZ)-induced diabetic (STZ-diabetic) mice. "
|1.||Plasminogen Activator Inhibitor 1
|4.||Plasminogen Activators (Plasminogen Activator)
|6.||Adenosine Diphosphate (ADP)
|7.||Acetic Acid (Vinegar)
|8.||NG-Nitroarginine Methyl Ester (L-NAME)
|9.||Methacholine Chloride (Methacholine)
|10.||Tannins (Tannic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)